Praveen R Juvvadi
Overview
Explore the profile of Praveen R Juvvadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dome P, Jeong P, Nam G, Jang H, Rivera A, Floyd Averette A, et al.
Proc Natl Acad Sci U S A
. 2024 Dec;
122(1):e2419883121.
PMID: 39739817
Invasive fungal infections are a leading cause of death worldwide. Translating molecular insights into clinical benefits is challenging because fungal pathogens and their hosts share similar eukaryotic physiology. Consequently, current...
2.
Dome P, Jeong P, Nam G, Jang H, Rivera A, Floyd Averette A, et al.
bioRxiv
. 2024 Oct;
PMID: 39386510
Significance: Invasive fungal infections cause significant mortality worldwide, and current antifungal treatments are often ineffective, toxic, or face growing resistance. This research identifies calcineurin (CaN), a critical protein for fungal...
3.
Maji A, Soutar C, Zhang J, Lewandowska A, Uno B, Yan S, et al.
Nature
. 2023 Nov;
623(7989):1079-1085.
PMID: 37938782
Decades of previous efforts to develop renal-sparing polyene antifungals were misguided by the classic membrane permeabilization model. Recently, the clinically vital but also highly renal-toxic small-molecule natural product amphotericin B...
4.
Rivera A, Lim W, Park E, Dome P, Hoy M, Spasojevic I, et al.
mBio
. 2023 Sep;
14(5):e0181023.
PMID: 37737622
Fungal infections cause significant morbidity and mortality globally. The therapeutic armamentarium against these infections is limited, and the development of antifungal drugs has been hindered by the evolutionary conservation between...
5.
Rivera A, Lim W, Park E, Dome P, Hoy M, Spasojevic I, et al.
bioRxiv
. 2023 Jun;
PMID: 37333270
Importance: Fungal infections cause significant morbidity and mortality globally. The therapeutic armamentarium against these infections is limited and development of antifungal drugs has been hindered by the evolutionary conservation between...
6.
Juvvadi P, Bobay B, Cole D, Awwa M, Steinbach W
J Fungi (Basel)
. 2022 Dec;
8(12).
PMID: 36547614
Calcineurin (CN) is an attractive antifungal target as it is critical for growth, stress response, drug resistance, and virulence in fungal pathogens. The immunosuppressive drugs, tacrolimus (FK506) and cyclosporin A...
7.
Hoy M, Park E, Lee H, Lim W, Cole D, DeBouver N, et al.
mBio
. 2022 May;
13(3):e0104922.
PMID: 35604094
Calcineurin is an essential virulence factor that is conserved across human fungal pathogens, including Cryptococcus neoformans, Aspergillus fumigatus, and Candida albicans. Although an excellent target for antifungal drug development, the...
8.
Shwab E, Juvvadi P, Shaheen S, Allen 4th J, Waitt G, Soderblom E, et al.
J Fungi (Basel)
. 2022 Apr;
8(4).
PMID: 35448585
Cellular recycling via autophagy-associated proteins is a key catabolic pathway critical to invasive fungal pathogen growth and virulence in the nutrient-limited host environment. Protein kinase A (PKA) is vital for...
9.
Gobeil S, Bobay B, Juvvadi P, Cole D, Heitman J, Steinbach W, et al.
mBio
. 2021 Nov;
12(6):e0300021.
PMID: 34809463
Calcineurin is a critical enzyme in fungal pathogenesis and antifungal drug tolerance and, therefore, an attractive antifungal target. Current clinically accessible calcineurin inhibitors, such as FK506, are immunosuppressive to humans,...
10.
Shaheen S, Juvvadi P, Allen 4th J, Shwab E, Cole D, Asfaw Y, et al.
Antimicrob Agents Chemother
. 2021 Jul;
65(10):e0068221.
PMID: 34310205
Invasive aspergillosis (IA) due to Aspergillus fumigatus is a deadly infection for which new antifungal therapies are needed. Here, we demonstrate the efficacy of a Gwt1 inhibitor, APX2041, and its...